REVERSAL OF MUCOSITIS BY GMSC-BASED THERAPY

基于 GMSC 的疗法逆转粘膜炎

• 批准号: 8169526
• 负责人: PETRA E WILDER-SMITH
• 金额: $ 0.21万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8169526
• 关键词: Adverse effects; Body Weight; Bone Marrow Transplantation; California; Cell Therapy; Cells; Clinical; Colitis; Computer Retrieval of Information on Scientific Projects Database; Coupled; Disease model; Dose; Exhibits; Funding; Gastrointestinal tract structure; Gingiva; Grant; Head; Homing; Immune; In Vitro; Inflammation; Inflammatory; Inflammatory Infiltrate; Injury; Institution; Interleukin-17; Laboratories; Mediator of activation protein; Microscopy; Molecular Biology; Mucositis; Mus; Optical Coherence Tomography; Patients; Radiation; Recruitment Activity; Regulatory T-Lymphocyte; Research; Research Personnel; Resources; School Dentistry; Severities; Site; Source; Stem cells; T-Lymphocyte; Technology; Testing; Tissues; United States National Institutes of Health; Universities; base; cancer therapy; chemotherapy; craniofacial; cytokine; human stem cells; in vivo; self-renewal; stem cell population

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Center for Craniofacial Molecular Biology, School of Dentistry, University of Southern California Mucositis of the alimentary tract (AT) is a debilitating side effect of cancer therapies in a high percentage of patients receiving chemotherapy, bone marrow transplantation, and high-dose radiation to the head and neck.Recent studies from our laboratory have isolated a new population of stem cells from human gingiva, an easily accessible tissue source, namely GMSC, which exhibit not only multipotent differentiation and self-renewal capacities, but also possess distinct immunomodulatory functions. Cell-based therapy with GMSC significantly ameliorated both clinical and histopathological severities of the colonic inflammation in the experimental murine colitis, presumably by suppressing inflammatory infiltrates, specifically interleukin-17 (IL-17) secreting cells, and a myriad of inflammatory cytokines/mediators, and recruiting regulatory T cells (Tregs) at the colonic sites. In another disease model of mucosal inflammation induced by chemotherapy, we observed a significant reversal of AT mucositis and regain of body weight in nearly 100% of mice undergoing an exploratory one dose treatment with GMSC Experimental Approaches: We will examine the immunomodulatory effects of GMSC on Treg and Th17 functions and how they contribute to mucositis using both in vitro and in vivo studies. Optical coherence tomography (OCT) coupled with multiphoton microscopy (MMP) technology will be utilized to decipher stem cell homing to mucositic sites. We will test whether adaptive transfer with Pan-T cells, ex vivo expanded Tregs, and pharmacologic immune boosting therapies can reverse mucosal injuries.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 美国南加州大学牙科学院颅面分子生物学中心 消化道粘膜炎（AT）是癌症治疗的一种使人衰弱的副作用，在接受化疗、骨髓移植和头颈部高剂量放疗的患者中，AT的比例很高。我们实验室最近的研究从人类牙龈中分离出一种新的干细胞群，即GMSC，它不仅表现出多能分化和自我更新能力，还具有明显的免疫调节功能。基于细胞的GMSC治疗显著改善了实验性小鼠结肠炎中结肠炎症的临床和组织病理学严重程度，推测是通过抑制炎性浸润，特别是白介素-17（IL-17）分泌细胞和无数炎性细胞因子/介质，并在结肠部位募集调节性T细胞（TCFs）。在另一种由化疗诱导的粘膜炎症的疾病模型中，我们观察到AT粘膜炎的显著逆转和体重的恢复，几乎100%的小鼠经历了GMSC的探索性单剂量治疗 实验方法：我们将使用体外和体内研究来检查GMSC对Treg和Th 17功能的免疫调节作用，以及它们如何导致粘膜炎。光学相干断层扫描（OCT）与多光子显微镜（MMP）技术相结合，将用于破译干细胞归巢粘膜网站。我们将测试是否适应性转移与泛T细胞，离体扩增的T细胞，和药理学免疫增强疗法可以逆转粘膜损伤。